New Hepatitis C Treatment

Published Online: Friday, February 24, 2012
Follow Pharmacy_Times:
The standard treatment for hepatitis C, interferon and ribavirin, cures just 45% of those who receive it. There are now several dozen new drugs for the disease under development, and 2 were approved by the FDA in 2011: telaprevir and boceprevir. The new drugs, which directly attack the virus that causes hepatitis C with minimal impact on the human host, have raised hopes of shorter treatment times and higher cure rates. Researchers are also looking at ways of tailoring treatment to individual patients based on genetic testing.
 
To learn more, check out this video:

Related Articles
Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.
Through the Pharmacist Connect program, pharmacists from chain member companies provided 2014 NACDS Total Store Expo attendees with immunizations and other pharmacy services.
Although many pharmacists express concerns about the state of the pharmacy job market, the good news is the demand for pharmacists seems to be increasing.
In several countries, increases in the incidence of inflammatory bowel disease have been observed closely following regulatory approval of sucralose.
Latest Issues
$auto_registration$